Clarivate Introduces New OFF-X ™ Platform for Preclinical and Clinical Safety Intelligence

Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has launched the new OFF-X™ platform, an enhanced solution for preclinical and clinical safety intelligence in biopharma. The platform offers a seamless user experience and unique translational insights, delivering important drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence™, OFF-X™ provides a comprehensive resource for safety information, streamlining processes and enhancing efficiency.

Key improvements include an 80% reduction in loading times for targets, drugs, drug combinations, and adverse events, faster search capabilities, clearer visual design, full-screen visualization, and additional analytic tools. The platform empowers users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities, and de-risk assets across all phases of drug R&D and post-marketing.

Positive

• Launch of enhanced OFF-X™ platform for improved safety intelligence
• 80% reduction in loading times for key data
• Integration with Cortellis Drug Discovery Intelligence™ for comprehensive safety information
• Enhanced functionality including faster search and additional analytic tools

Negative

• None.

Empowering biopharma with enhanced safety insights to anticipate risks and unlock new competitive advantages

LONDON, July 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the launch of the new OFF-X™ platform. The enhanced solution offers a seamless user experience and unique translational insights. It delivers crucial drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence™, OFF-X™ provides a comprehensive, one-stop resource for safety information, streamlining processes and enhancing efficiency which ultimately delivers a competitive edge.

The new platform features an upgraded technology stack and enhanced functionality while retaining its core capabilities. These improvements include an 80% reduction in loading times for targets, drugs, drug combinations and adverse events. The platform now offers faster search capabilities, a clearer visual design, full-screen visualization and additional analytic tools.

Justin Hubbard, Vice President, Product Management, Life Sciences and Healthcare at Clarivate, said:  "The launch of the new OFF-X™ platform underscores our dedication to providing actionable, comprehensive solutions in life sciences and healthcare. OFF-X revolutionizes access to safety information across all drug R&D and post-marketing phases, with speed and customization. By combining our safety intelligence with advanced analytics, we empower clients to accelerate the delivery of safe, effective and commercially successful treatments to patients."

OFF-X empowers users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities and de-risk assets across all phases of drug R&D and post-marketing, bolstering confident development and investment decisions.

Learn more about OFF-X here.

About OFF-X™

OFF-X is the new translational safety intelligence platform that facilitates integrated preclinical toxicity data, clinical and pharmacovigilance adverse event data, visualizations and preclinical safety analytics. Updated daily, the platform incorporates wide-ranging analytics and visualizations, as well as comprehensive range of safety information sources and datasets, including a range of over 15,000 targets and more than 39,000 drugs & biologics, populated with almost 3 million expertly curated safety alerts associated to 14,000 adverse events and toxicity endpoints.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact:
Luna Ivkovic,
External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-introduces-new-off-x--platform-for-preclinical-and-clinical-safety-intelligence-302207891.html

SOURCE Clarivate Plc

FAQ

What is the new OFF-X™ platform launched by Clarivate (CLVT)?

The new OFF-X™ platform is an enhanced solution for preclinical and clinical safety intelligence in biopharma, offering a seamless user experience and unique translational insights to proactively identify risks in drug development.

How does the new OFF-X™ platform improve efficiency for Clarivate (CLVT) users?

The platform offers an 80% reduction in loading times for targets, drugs, drug combinations, and adverse events, faster search capabilities, clearer visual design, and additional analytic tools, streamlining processes and enhancing efficiency.

What are the key benefits of Clarivate's (CLVT) new OFF-X™ platform for drug development?

OFF-X™ empowers users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities, and de-risk assets across all phases of drug R&D and post-marketing, supporting confident development and investment decisions.

How does Clarivate's (CLVT) OFF-X™ platform integrate with other solutions?

OFF-X™ is fully integrated with Cortellis Drug Discovery Intelligence™, providing a comprehensive, one-stop resource for safety information in drug development and research.